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Etent Overlap
n Patients Undergoing
rug-Eluting Stent Implantation
read with interest the paper by Räber et al. (1) comparing patients
ith multiple drug-eluting stents (DES) in a vessel with overlap
ith patients with multiple DES in a vessel without overlap and
atients with 1 DES/vessel. The authors demonstrated that major
dverse cardiac events were more common in patients with DES
verlap than in the other groups at 3 years.
First, because the original study demonstrated a significant
ifference between sirolimus- and paclitaxel-eluting stent groups
2), it would be of great help if the authors would provide data
tratified by stent type. Second, overlapping stent implantation was
erformed for dissection in some cases (28 of 138, 20%). Dissec-
ion might be a cause of creatine kinase elevation (myocardial
nfarction) rather than overlapping stent implantation itself. To
larify this point, it would be of great help if the authors would
rovide data about peri-procedural creatine kinase elevation and its
ssociation with dissection. Third, target lesion revascularization
eems to be determined on a per-patient basis. Because there were
wice as many lesions/patient (2.0, 394 in 199 patients) in patients
ith multiple DES in a vessel without overlap compared with the
ther groups (1.0, 138 in 134 patients; 1.1, 778 in 679 patients),
er-patient analysis might overestimate target lesion revasculariza-
ion rate in patients with multiple DES in a vessel without overlap.
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eply
e appreciate the interest of Dr. Kaneda in our study (1) reporting
n the angiographic and long-term clinical outcome in patients
ith first-generation drug-eluting stent (DES) overlap and takehe opportunity to present clinical outcome data up to 3 yearstratified/stent type (Table 1) (2). Crude event rates among
atients with DES overlap (A), patients with multiple DES in a
essel without overlap (B), and patients with a single stent in a
essel (C) were similar between stent types. Corresponding crude
nd adjusted hazard ratios (HRs) varied to some extent between
tent types, but confidence interval (CI) overlapped widely, and
ests for interaction between HRs and stent type were negative,
uggesting the absence of a relevant impact of stent type on the
linical outcome among patients with DES overlap.
Dr. Kaneda appropriately raises the question of whether dissec-
ions were the source of peri-procedural myocardial infarction
MI) rather than overlapping stent implantations per se. Indeed,
eri-procedural MI, defined as any MI occurring within 48 h of
he index procedure were more frequent among patients with DES
verlap due to dissection (11.1%) as compared with patients with
ES overlap related to other indications (0.9%, relative risk: 13.3,
5% CI: 1.3 to 133.0, p  0.03). When excluding peri-procedural
Is from the analyses, however, we found HRs of MI comparing
atients with DES overlap and patients with multiple DES in a
essel without overlap similar to those reported in our paper (1):
rude HR: 1.30 (95% CI: 0.47 to 3.58); adjusted HR: 2.07 (95%
I: 0.56 to 7.75). Accordingly, dissections might have contributed
n part to the observed impact of stent overlap but do not explain
he adverse effect emerging during longer-term follow-up in terms
f ischemic end points (death or MI) and restenosis.
We concur with Dr. Kaneda that patients with multiple target
esions are more likely to experience target lesion revascularizations
TLRs) than patients with single lesions. In our study, the hazard
f TLR was 1.88 times higher in patients with 2 lesions (95% CI:
.20 to 2.96) and 3.05 times higher in patients with 3 lesions (95%
I: 1.50 to 6.22) as compared with patients with single lesions
p for trend 0.01). We therefore adjusted, as reported in Table 5
f our article (1), analyses for the number of lesions in the
ultivariable model. The HR of TLR comparing patients with
ES overlap and patients with multiple DES without overlap was
.26 in the crude analysis (95% CI: 0.76 to 2.11), 1.83 in an
nalysis adjusted for the number of target lesions (95% CI: 1.06 to
.19), and 1.94 in the fully adjusted analysis reported in Table 5 of
ur article (95% CI: 1.05 to 3.58) (1).
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